Skip to main content
SpringerLink
Log in

The future of valproate

  • Chapter
Valproate

Part of the book series: Milestones in Drug Therapy ((MDT))

  • 356 Accesses

Abstract

Valproate (VPA) currently has established efficacy and its use is expanding for the treatment of epilepsy, migraine headache and acute mania, as addressed elsewhere in this volume, but the future of VPA is unknown because it depends on whether safer and more effective medications become available for these conditions. Nevertheless, in this chapter we speculate on the future of VPA based on the current knowledge of its properties and use.

Deceased October 18, 1997.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Fariello RG, Varasi M, Smith MC (1995) Valproic acid mechanisms of action. In: RH Levy, RH Mattson, BS Meldrum (eds): Antiepileptic Drugs,Fourth Edition. Raven Press, New York, 581–588

    Google Scholar 

  2. Chapman A, Keane PE, Meldrum BS, Simiand J, Vernieres JC (1982) Mechanism of anti-convulsant action of valproate. Prog Neurobiol 19: 315–359

    Article  PubMed  CAS  Google Scholar 

  3. Löscher W, Nau H, Siemes H (1988) Penetration of valproate and its active metabolites into cerebrospinal fluid of children with epilepsy. Epilepsia 29: 311–316

    Article  PubMed  Google Scholar 

  4. Löscher W, Nau H (1983) Distribution of valproic acid and its metabolites in various brain areas of dogs and rats after acute and prolonged treatment. J Pharmacol Exp Ther 226(3): 845–854

    Google Scholar 

  5. McLean MJ, MacDonald RL (1986) Sodium valproate, but not ethosuximide, produces use and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 237: 1001–1011

    CAS  Google Scholar 

  6. Baillie TA, Sheffels PR (1995) Valproic acid chemistry and biotransformation. In: RH Levy, RH Mattson, BS Meldrum (eds): Antiepileptic Drugs,Fourth Edition. Raven Press, New York, 589–604

    Google Scholar 

  7. Bolanos JP, Medina JM (1997) Effect of valproate on the metabolism of the central nervous system. Life Sciences 60(22): 1933–1942

    Article  PubMed  CAS  Google Scholar 

  8. Levy RH, Shen DD (1995) Valproic Acid absorption, distribution, and excretion. In: RH Levy, RH Mattson, BS Meldrum (eds): Antiepileptic Drugs,Fourth Edition. Raven Press, New York 605–619

    Google Scholar 

  9. Bourgeois BFD (1995) Valproic acid clinical use. In: RH Levy, RH Mattson, BS Meldrum (eds): Antiepileptic Drugs, Fourth Edition. Raven Press, New York 633–639

    Google Scholar 

  10. Klotz U (1982) Bioavailability of a slow release preparation of valproic acid under steady state conditions. Int J Clin Pharmacol Ther Toxicol 20(1): 24–26

    PubMed  CAS  Google Scholar 

  11. Dreifuss FE (1995) Valproic acid toxicity. In: RH Levy, RH Mattson, BS Meldrum (eds): Antiepileptic Drugs, Fourth Edition. Raven Press, New York, 641–648

    Google Scholar 

  12. Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB (1987) Valproic acid hepatic fatalities: a retrospective review. Neurology 37(3): 379–385

    Article  PubMed  CAS  Google Scholar 

  13. Dreifuss FE, Langer DH, Moline KA, Maxwell JE (1989) Valproic acid hepatic fatalities: II. US experience since 1984. Neurology 39(2 Pt 1): 201–207

    Article  PubMed  CAS  Google Scholar 

  14. Zimmerman HJ, Ishak, KG (1982) Valproate-induced hepatic injury: analyses of 23 fatal cases. Hepatology 2(5): 591–597

    Article  PubMed  CAS  Google Scholar 

  15. Kay JD, Hilton-Hones D, Hyuman N (1986) Valproate toxicity and ornithine carbamoyltransferase deficiency. Lancet 2: 1283–1284

    Article  PubMed  CAS  Google Scholar 

  16. Siemes H, Nau H, Schultze K, et al. (1993) Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity. Epilepsia 34: 332–346

    Article  PubMed  CAS  Google Scholar 

  17. Kesterson JW, Granneman GR, Machinist JM (1984) The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic biochemical and histopathologic studies. Hepatology 4: 1143–1152

    Article  PubMed  CAS  Google Scholar 

  18. Fisher E, Siemes H, Pund R, Wittfoht W, Nau H (1992) Valproate metabolites in serum and urine during antiepileptic therapy in children with infantile spasms: abnormal metabolite pattern associated with reversible hepatotoxicity. Epilepsia 33 (1): 165–171

    Article  PubMed  CAS  Google Scholar 

  19. Coulter DL (1984) Carnitine deficiency: a possible mechanism for valproate hepatotoxicity. Lancet 1: 689

    Article  PubMed  CAS  Google Scholar 

  20. Delgado-Escueta AV, Janz D (1992) Pregnancy and teratogenesis in epilepsy. Neurology 42 (Suppl 5): 1–160

    Google Scholar 

  21. Nau H, Hauck R-S, Ehlers K (1991) Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics, and possible mechanisms. Pharmacol Toxicol 69: 310–321

    Article  PubMed  CAS  Google Scholar 

  22. Nau H, Löscher W (1984) Valproic acid and metabolites: pharmacological and toxicological studies. Epilepsia 25 (Suppl 1): S14—S22

    PubMed  Google Scholar 

  23. Gram L (1992) Studies on 2-n-propyl-2(E)-pentenoate (delta 2 (E)-valproate) in man. Pharm Weekbl Sci 14(3 A): 159–160

    Article  PubMed  CAS  Google Scholar 

  24. Löscher W (1992) Pharmacological, toxicological and neurochemical effects of delta 2(E)valproate in animals. Pharm Weekbl Sci 14 (3 A): 144–145

    Google Scholar 

  25. Vorhees CV, Acuff-Smith KD, Weisenburger WP, Minck DR, Berry JS, Setchell KD, Nau H (1991) Lack of teratogenicity of trans-2-ene-valproic acid compared to valproic acid in rats. Teratology 43 (6): 583–590

    Article  PubMed  CAS  Google Scholar 

  26. Sokolova S, Schmitz D, Zhang Cl, Löscher W, Heinemann U (1998) Comparison of effects of valproate and trans-2-en-valproate on different forms of epileptiform activity in rat hippocampal and temporal cortex slices. Epilepsia 39(3): 251–258

    Article  PubMed  CAS  Google Scholar 

  27. Palaty JH, Abbott FS (1995) Structure-activity relationships of unsaturated analogues of valproic acid. J Medicin Chem 38(17): 3398–3406

    Article  CAS  Google Scholar 

  28. Bialer M (1991) Clinical pharmacology of valpromide. Clin Pharmacokinet 20:114–122

    Article  PubMed  CAS  Google Scholar 

  29. Bialer M, Kadry B, Abdul-Hai A, Haj-Yehia A, Sterling J, Herzig Y, Shirvan M (1996) Pharmacokinetic and pharmacodynamic analysis of (E)-2-ene valproyl derivatives of glycine and valproyl derivatives of nipecotic acid. Biopharmac Drug Dispos 17: 565–575

    Article  CAS  Google Scholar 

  30. Scott KR, Adesioye S, Ayuk PB, Edafiogho IQ, John D, Kodwin P, Maxwell-Irving T, Moore JA, Nicholson JM (1994) Synthesis and evaluation of amino analogues of valproic acid. Pharmaceutic Res 11(4): 571–574

    Article  CAS  Google Scholar 

  31. Bojic U, Elmazar MM, Hauck RS, Nau H (1996) Further branching of valproate-related carboxylic acids reduces the teratogenic activity, but not the anticonvulsant effect. Chem Res Toxicol 9(5): 866–870

    Article  PubMed  CAS  Google Scholar 

  32. Hadad S, Vree TB, van der Kleijn E, Bialer M (1993) Pharmacokinetic analysis and anti-convulsant activity of two polyesteric prodrugs of valproic acid. Biopharmac Drug Dispos 14(1): 51–59

    Article  CAS  Google Scholar 

  33. Hadad S, Vree TB, van der Kleijn E, Bialer M (1992) Pharmacokinetic analysis ester prod-rugs of valproic acid. JPharmcokinetic Sci 81(10): 1047–1050

    Article  CAS  Google Scholar 

  34. Tang W, Abbott FS (1997) A Comparative investigation of 2-propyl-4-pentenoic acid (4-ene VPA) and its a-fluorinated analogue — Phase II metabolism and pharmacokinetics. Drug Metabo Dispos 25 (2): 219–227

    CAS  Google Scholar 

  35. Tantisira B, Tantisira MH, Patarapanich C, Sooksawte T, Chunngam T (1997) Preliminary evaluation of the anticonvulsant activity of a valproic acid analog: N-(2-propylpentanoyl) urea. Research Comm Molecular Path Pharmacology 97(2): 151–164

    CAS  Google Scholar 

  36. Sobaniec W, Sobaniec-Lotowska M (1994) The effects of sodium valproate and its metabolites (5-OH-VPA and 4-OH-VPA) on electroconvulsions in rats. Materia Medica Polona 26:29–32

    PubMed  CAS  Google Scholar 

  37. Dreifuss FE, Fountain NB (1998) Classification of epileptic seizures and the epilepsies with drugs of choice. In: MJ Eadie, F Vajda (eds): Handbook of Experimental Pharmacology, Antiepileptic Drugs II. Springer-Verlag, Berlin, in press

    Google Scholar 

  38. Jeavons PM, Bishop A, Harding GFA (1986) The prognosis of photosensitivity. Epilepsia 27: 569–575

    Article  PubMed  CAS  Google Scholar 

  39. Mackay FJ, Wilton LV, Pearce GL, Freemantle SN, Mann RD (1997) Safety of long-term lamotrigine in epilepsy. Epilepsia 38(8): 881–886

    Article  PubMed  CAS  Google Scholar 

  40. Kaufman DW, Kelly JP, Anderson T, Harmon DC, Shapiro S (1997) Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia 38: 1265–1269

    Article  PubMed  CAS  Google Scholar 

  41. Leach JP (1997) Polypharmacy with anticonvulsants — focus on synergism. CNS Drugs 8(5): 366–375

    Article  CAS  Google Scholar 

  42. Brodie MJ, Yuen AW (1997) Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 study group. Epilepsy Res 26(3): 423–32

    Article  PubMed  CAS  Google Scholar 

  43. Silver JM, Shin C, McNamara JO (1991) Antiepileptogenic effects of conventional anti-convulsants in the kindling model of epilepsy. Ann Neurol 29: 356–363.

    Article  PubMed  CAS  Google Scholar 

  44. McElroy SL, Keck PE, Pope HG, Hudson JI (1993) Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. J Clin Psychopharmacol 12: 42S–52S

    Google Scholar 

  45. Post RM, Ketter TA, Denicoff K, Pazzaglia PJ, Leverich GS, Marangell LB, Callahan AM, George MS, Frye MA (1996) The place of anticonvulsant therapy in bipolar illness. Psychopharmacol 128(2): 115–129

    Article  CAS  Google Scholar 

  46. Freeman TW, Clothier JL, Pazzaglia P, Lesern MD, Swann AC (1992) A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 149: 108–111

    PubMed  CAS  Google Scholar 

  47. Petty F (1995) GABA and mood disorders: a brief review and hypothesis. J Affect Disord 34(4): 275–281

    Article  CAS  Google Scholar 

  48. Jacobsen FM (1993) Low-dose valproate: a new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome. J Clin Psychiatry 54(6): 229–234

    CAS  Google Scholar 

  49. Stoll AL, Banov M, Kolbrener M, Mayer PV, Tohen M, Strakowski SM, Castillo J, Suppes T, Cohen BM (1994) Neurologic factors predict favorable valproate response in bipolar and schizoaffective disorders. J Clin Psychopharmacol 14(5): 311–313

    Article  PubMed  CAS  Google Scholar 

  50. Peichev L (1992) Mechanisms of neurotransmission of valproate sodium in suppressing barbiturate and phenytoin withdrawal syndrome. Folia Medica 34 (2): 14–19

    PubMed  CAS  Google Scholar 

  51. Silberstein SD (1996) Divalproex sodium in headache: literature review and clinical guidelines. Headache 36(9): 547–555

    Article  PubMed  CAS  Google Scholar 

  52. Rosen JA (1983) Observations on the efficacy of propranolol for the prophylaxis of migraine. Ann Neurol 13 (1): 92–93

    Article  PubMed  CAS  Google Scholar 

  53. Cutrer FM, Moskowitz MA (1996) The actions of valproate and neurosteroids in a model of trigeminal pain. Headache 36(10): 579–585

    Article  PubMed  CAS  Google Scholar 

  54. Maes M, Calabrese J, Jayathilake K, Meltzer HY (1997) Effects of subchronic treatment with valproate on L-5-HTP-induced cortisol responses in mania: evidence for increased central serotonergic neurotransmission. Psychiatry Res 71(2): 67–76

    Article  PubMed  CAS  Google Scholar 

  55. Pens JB, Perera GL, Devendra SV, Lionel ND (1980) Sodium valproate in trigeminal neuralgia. Med J Australia 2(5): 278

    Google Scholar 

  56. Hering R, Kuritzky A (1989) Sodium valproate in the treatment of cluster headache: an open clinical trial. Cephalgia 9(3): 195–198

    CAS  Google Scholar 

  57. Fahn S (1979) Posthypoxic action myoclonus: review of the literature and report of two new cases with response to valproate and estrogen. Advances in Neurology 26: 49–84

    PubMed  CAS  Google Scholar 

  58. Fouillet N, Wiart L, Arne P, Alaoui P, Petit H, Barat M (1995) Propriospinal myoclonus in tetraplegic patients: clinical, electrophysiological and therapeutic aspects. Paraplegia 33 (11): 678–681

    Article  PubMed  CAS  Google Scholar 

  59. Daoud AS, Zaki M, Shakir R, al-Saleh Q (1990) Effectiveness of sodium valproate in the treatment of Sydenham’s chorea. Neurology 40(7): 1140–1141

    Article  PubMed  CAS  Google Scholar 

  60. Przuntek H, Monninger P (1983) Therapeutic aspects of kinesiogenic paroxysmal choreoathetosis and familial paroxysmal choreoathetosis of the Mount and Reback type. J Neurol 230(3):163–169

    CAS  Google Scholar 

  61. Fredow G, Löscher W (1991) Effects of pharmacological manipulations of GABAergic neurotransmission in a new mutant hamster model of paroxysmal dystonia. Eur J Pharmacol 192(2): 107–219

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Comprehensive Epilepsy Program, Department of Neurology, University of Virginia School of Medicine, Charlottesville, VA, 22908, USA

    Nathan B. Fountain & Fritz E. Dreifuss

Authors
  1. Nathan B. Fountain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fritz E. Dreifuss
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmacology, Toxicology, and Pharmacy, School of Veterinary Medicine, BĂĽnteweg 17, Bldg. 225, D-30559, Hannover, Germany

    Wolfgang Löscher

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Basel AG

About this chapter

Cite this chapter

Fountain, N.B., Dreifuss, F.E. (1999). The future of valproate. In: Löscher, W. (eds) Valproate. Milestones in Drug Therapy. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8759-5_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8759-5_11

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9761-7

  • Online ISBN: 978-3-0348-8759-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation